The Medicines Company
8 Sylvan Way
Parsippany
New Jersey
07054
United States
Tel: 973-290-6000
Fax: 973-656-9898
Website: http://www.themedicinescompany.com/
Email: contactus@themedco.com
About The Medicines Company
The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.
501 articles about The Medicines Company
-
The Medicines Company And Alnylam Present Positive Results From ORION-1 Phase II Study Of Inclisiran (formerly PCSK9si)
11/15/2016
-
Alnylam And The Medicines Company Announce Publication Of Phase 1 Clinical Data With Inclisiran (ALN- PCSsc) In The New England Journal of Medicine
11/14/2016
-
The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase II Study Of PCSK9si
11/10/2016
-
The Medicines Company Abandons Development of Plaque Buster MDCO-216; Will Dump Cash Into PCSK9 Instead
11/8/2016
-
The Medicines Company Reports Third-Quarter 2016 Financial Results
10/26/2016
-
The Medicines Company To Announce Third Quarter Financial Results On October 26, 2016
10/18/2016
-
The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si
10/18/2016
-
The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY 2016 Annual Meeting And The ISAP 25th Annual Meeting
10/13/2016
-
The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY 2016 Annual Meeting And The ISAP 25th Annual Meeting
10/13/2016
-
The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si
10/6/2016
-
U.S. Bets $132 Million on The Medicines Company, $151.6 Million on Roche for Antibiotics Development
9/21/2016
-
The Medicines Company Losing Ground on News That Interim Data for Plaque Buster Med is Inconclusive
8/31/2016
-
The Medicines Company Reports Second-Quarter 2016 Business And Financial Results
7/27/2016
-
The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016
7/18/2016
-
Federal Circuit Rules For The Medicines Company In Angiomax (Bivalirudin) Patent Litigation
7/12/2016
-
The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE
6/27/2016
-
The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi
6/22/2016
-
The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700
6/14/2016
-
The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 – 20 In Boston
6/13/2016
-
The Medicines Company Prices $350 Million Of Convertible Notes
6/7/2016